Comparative 50% protective dose (PD50) assays were performed using a plaque-purified preparation of
Marek's disease virus (MDV) strain CVI-988 at the 65th chicken embryo fibroblast (CEF) passage level (MDV CVI-988 CEF65 clone C) and three commercial MD
vaccines: herpesvirus of turkeys (HVT) FC126, MDV CVI-988 CEF35, and a
bivalent vaccine composed of HVT FC126 and MDV
SB-1. In addition, comparative PD50 assays were performed in groups of chickens with maternal antibody to each of the three
vaccines. Three representatives of the newly emerged biovariant very virulent (vv) MDV strains-RB/1B, Tun, and Md5-were employed as challenge virus. The experiments made feasible the differentiation between virulent MDV and vvMDV strains, within serotype 1. Vaccination with CVI-988 clone C
vaccine resulted in PD50 estimates of about 5 plaque-forming units (PFUs) against challenge
infection with each of the three vvMDV strains. The PD50 estimate of CVI-988 clone C
vaccine was 12-fold below the PD50 of HVT FC126. The protective synergism of
bivalent vaccine, composed of HVT and
SB-1, was confirmed by groups given the lowest
vaccine doses. The
bivalent vaccine, however, resulted in incomplete protection in groups given the highest
vaccine doses. Homologous maternal
antibodies to serotype 1 caused a fivefold increase in the PD50 estimate of CVI-988 clone C. Heterologous maternal
antibodies against HVT did not interfere with efficacy of CVI-988 clone C vaccination. However, the combination of maternal
antibodies against both HVT and
SB-1 (serotypes 2 and 3) showed a strong adverse effect on CVI-988 clone C
vaccine.(ABSTRACT TRUNCATED AT 250 WORDS)